Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Scientists discover pathway that promotes muscle cell survival in mice

Scientists at the Salk Institute for Biological Studies have identified an enzyme that pumps up a cell's ability to maintain healthy muscle and restores normal muscle function in genetically engineered mice with weak muscles.

30 Apr 2007

New data supports safety of ranolazine but not its effectiveness

The anti-anginal medication ranolazine was shown to be safe in regard to certain outcomes but did not reduce the risk of major cardiovascular events such as death, heart attack or recurrent ischemia following acute coronary syndromes, according to a study in the April 25 issue of JAMA .

25 Apr 2007

Moonlighting enzyme linked to Friedreich's ataxia

Friedreich's ataxia is one of those diseases few have heard of unless you know someone with the condition.

25 Apr 2007

Ranolazine safe but not effective in reducing major cardiac events in ACS patients

25 Apr 2007

Medicare reimbursements at Wake Forest University Baptist Medical Center to continue

The Centers for Medicare & Medicaid Services (CMS) has announced that reimbursements for Medicare heart transplant cases performed at Wake Forest University Baptist Medical Center will continue uninterrupted.

24 Apr 2007

UNC-45 protein critical to proper formation of muscles

Proper formation of the proteins that power heart and skeletal muscle seems to rely on a precise concentration of a "chaperone" protein known as UNC-45, according to a new study.

24 Apr 2007

GP surgeries with specialist nurses can help save lives

One of the biggest research trials carried out in GP surgeries has confirmed that those with specialist cardiac nurse clinics can help to improve patients' lives.

24 Apr 2007

Remote monitoring for patients with chronic heart failure shows significant benefits

Researchers from Canada and Australia have found that the use of remote monitoring for patients with chronic heart failure has the potential to significantly improve clinical outcomes (mortality, morbidity and quality indicators).

21 Apr 2007

Vasogen and Grupo Ferrer to commercialize Celacade in Europe

Vasogen has announced a collaboration with Grupo Ferrer Internacional, S.A. ("Ferrer"), to commercialize Vasogen's Celacade technology for the treatment of chronic heart failure in the European Union and in certain Latin American countries.

19 Apr 2007

Link between psoriasis and diabetes and atherosclerosis

Psoriasis is a chronic skin condition characterized by thick, red, scaly plaques that itch and sometimes bleed, causing considerable discomfort and emotional stress for patients.

19 Apr 2007

Treatment costs fall and quality improves when patients use self-treatment tools

Encouraging patients to become involved in providing their own care can reduce the cost and improve the quality of long-term medical treatment, say researchers from Massachusetts General Hospital and Massachusetts Institute of Technology in PLoS Medicine this week.

18 Apr 2007

Gleevec available to patients in post-surgical GIST study

Investigators will begin offering Gleevec(R) (imatinib mesylate)* tablets to patients receiving placebo in a major North American clinical trial after an interim analysis showed participants with Kit-positive gastrointestinal stromal tumors treated with Gleevec following surgery were significantly less likely to experience a return of their cancer compared to those not taking this innovative therapy.

15 Apr 2007

Monitoring chronic heart failure patients' health by phone helps

Monitoring patients' health by phone can make a real difference to people with chronic heart failure, according to a study published on bmj.com.

15 Apr 2007

Cytokinetics initiates of phase II clinical trial for CK-1827452

Cytokinetics has announced the initiation of a Phase II clinical trials program evaluating CK-1827452, a novel cardiac myosin activator for the potential treatment of patients with either acutely decompensated or chronic heart failure.

15 Apr 2007

Report reveals cost of type 2 diabetes complications

A first-of-its-kind report looking at the prevalence and cost of type 2 diabetes complications shows that an estimated three out of five people (57.9 percent) with type 2 diabetes have at least one of the other serious health problems commonly associated with the disease, and that these health problems are taking a heavy financial toll on the United States.

11 Apr 2007

Breakthrough Australian pump could give heart patients new hope

Lead researcher Associate Professor Andy Tan said the heart pump's innovative design was based on a double-output centrifugal model that pushed the blood in a counter direction to ensure correct flow through both sides of the heart, and is the subject of a patent application.

11 Apr 2007

Abbott opens biotech facility in Puerto Rico

"This new facility is a key milestone for Abbott as we move to focus our resources and future growth on biologic and potent-drug manufacturing," said Lawrence Kraus, vice president of manufacturing, global pharmaceutical operations, Abbott.

11 Apr 2007

Brain's reaction to stress can damage a vulnerable heart

British scientists say they have found that a part of the brain responsible for functions such as learning and memory can also destabilise the heart during times of stress.

11 Apr 2007

Heart study observes 20th year in Forsyth County

Because of the 4,035 Forsyth County residents who participated in a long-running study of heart disease risk factors, researchers at Wake Forest University Baptist Medical Center and colleagues have made major findings such as how being overweight is associated with becoming disabled and that passive smoking increases the risk of hardening of the arteries.

9 Apr 2007

Alteon expands agreement with Biorap Technologies

Alteon has announced that it has entered into an expanded licensing agreement with BioRap Technologies, the commercialization arm of the Rappaport Family Institute for Research, Technion University, Israel, for all diagnostic devices or products for predictive purposes in vascular or cardiac diseases, including diagnostic assays for the measurement of the haptoglobin protein (Hp).

7 Apr 2007